Oncology. 1992;49(6):467-73.

Experience with intraperitoneal alpha-2a interferon.

Nicoletto MO, Fiorentino MV, Vinante O, Prosperi A, Tredese F, Tumolo S, Cima GP, Monfardini S.

Source

Division of Medical Oncology, University Hospital, Padua, Italy.

Abstract

Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal alpha 2a-Interferon. The usual single dosage was 54 x 10(6) U at weekly intervals for four times (eight times in responders): 10 histologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. alpha 2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.

PMID:: 1465286; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Medical

Supplemental Content

Save items

Related citations in PubMed

A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. [Blut. 1989]
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H. Blut. 1989 Jun; 58(6):275-8.
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. [J Clin Oncol. 1992]
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp S, Barna B, Boyett J, Bukowski RM. J Clin Oncol. 1992 May; 10(5):804-9.
Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. [Eur J Cancer. 1995]
Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V, Yap A. Eur J Cancer. 1995; 31A(1):35-40.
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. [J Clin Oncol. 1993]
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. J Clin Oncol. 1993 Jul; 11(7):1368-75.
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. [J Clin Oncol. 1996]
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, et al. J Clin Oncol. 1996 Aug; 14(8):2234-41.

See reviews... See all...

Cited by 1 PubMed Central article

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission? [Int J Med Sci. 2004]
A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?
Nicoletto MO, Tumolo S, Falci C, Donach M, Visonà E, Rosabian A, Nascimben O, Cima GP, Vinante O, Azzoni P, et al. Int J Med Sci. 2004; 1(2):116-125. Epub 2004 Jun 1.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Experience with intraperitoneal alpha-2a interferon.
Experience with intraperitoneal alpha-2a interferon.
Oncology. 1992 ;49(6):467-73.

PubMed
Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carc...
Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast.
Hum Pathol. 2003 Nov ;34(11):1163-9.

PubMed
Efficacy of an experimental fasciolicide against immature and mature Fasciola he...
Efficacy of an experimental fasciolicide against immature and mature Fasciola hepatica in artificially infected calves.
Parasitol Res. 2004 Feb ;92(3):211-4. Epub 2003 Dec 3 .

PubMed
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Strahlenther Onkol. 2003 Dec ;179(12):801-11.

PubMed
The effects of different alcoholic drinks on lipids, insulin and haemostatic and...
The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in older men.
Thromb Haemost. 2003 Dec ;90(6):1080-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: